Juno scrambles to avoid being crushed by a hold, but experts question its best case scenario
“Fludarabine in some ways acts like a dose amplifier,” says Juno CEO Hans Bishop, explaining the company’s theory of what went wrong.
About the last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
